Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping the brain to fight opioid relapse?

NCT ID NCT04920864

Knowledge-focused Sponsor: Wayne State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a non-invasive brain stimulation technique called rTMS can help people with opioid use disorder stick with their methadone treatment and avoid relapse. Researchers will measure how stress affects cravings and decision-making. 32 adults currently in methadone or buprenorphine treatment will participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 32 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Meet DSM-5 criteria for OUD; 2. In methadone or buprenorphine treatment 3. Age 21-70 yr; 4. Right handed; 5. Males and non-pregnant/non-lactating females; 6. Cognitively intact (total IQ score \>80); 7. Use alcohol and/or marijuana \<4 times per week; each "time" should consist of \<2 marijuana "joint" equivalent and \<4 alcoholic drinks. Exclusion Criteria: 1. Acutely under the influence of any substance (except methadone or buprenorphine) during session; 2. Current, regular (\>2 times/week) use of illicit drugs other than opioids (except cannabis); 3. Any past 24 hour use of drugs other than opioids or nicotine; 4. Urinalysis positive for pregnancy; 5. Medical conditions prohibiting use of rTMS; 6. Lifetime psychotic, bipolar, or potentially antisocial personality disorder; 7. Untreated or uncontrolled past-year diagnosis of major depression, generalized anxiety disorder, obsessive compulsive disorder, or post traumatic stress disorder; 8. Past-month SUD other than OUD or tobacco use disorder; 9. Acute/unstable illness making it unsafe for participation; 10. Any prohibited medications including: medications that lower seizure threshold, certain psychiatric medications, or prescription pain medications; 11. Chronic head or neck pain; 12. Past-month participation in a research study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid-use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opioid-use disorder

Contacts and locations

Locations

  • Tolan Park Medical Building

    Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.